Lara P - Search Results

1

Current and future therapeutic approaches in locally advanced (stage III) non-small cell lung cancer.

Davies A, Gandara DR, Lara P, Goldberg Z, Roberts P, Lau D. Davies A, et al. Among authors: lara p. Semin Oncol. 2002 Jun;29(3 Suppl 12):10-6. doi: 10.1053/sonc.2002.34257. Semin Oncol. 2002. PMID: 12170446 Review.

2

High-dose toremifene as a cisplatin modulator in metastatic non-small cell lung cancer: targeted plasma levels are achievable clinically.

Lara PN Jr, Gandara DR, Wurz GT, Lau D, Uhrich M, Turrell C, Raschko J, Edelman MJ, Synold T, Doroshow J, Muggia F, Perez EA, DeGregorio M. Lara PN Jr, et al. Cancer Chemother Pharmacol. 1998;42(6):504-8. doi: 10.1007/s002800050852. Cancer Chemother Pharmacol. 1998. PMID: 9788578 Clinical Trial.

3

Malignant thymoma: current status and future directions.

Lara PN Jr. Lara PN Jr. Cancer Treat Rev. 2000 Apr;26(2):127-31. doi: 10.1053/ctrv.1999.0159. Cancer Treat Rev. 2000. PMID: 10772969 Review.

4

Gemcitabine/carboplatin combination regimens: importance of dose schedule.

Gandara DR, Lau DH, Lara PN Jr, Edelman MJ. Gandara DR, et al. Among authors: lara pn jr. Oncology (Williston Park). 2000 Jul;14(7 Suppl 4):26-30. Oncology (Williston Park). 2000. PMID: 10960942 Free article. Review.

5

Evolution of combined modality therapy for stage III non-small-cell lung cancer.

Gandara DR, Edelman M, Lara P, Roberts P, Leigh B. Gandara DR, et al. Among authors: lara p. Oncology (Williston Park). 2000 Jul;14(7 Suppl 5):35-41. Oncology (Williston Park). 2000. PMID: 10981289 Review.

6

Twice-weekly paclitaxel and weekly carboplatin with concurrent thoracic radiation followed by carboplatin/paclitaxel consolidation for stage III non-small-cell lung cancer: a California Cancer Consortium phase II trial.

Lau D, Leigh B, Gandara D, Edelman M, Morgan R, Israel V, Lara P, Wilder R, Ryu J, Doroshow J. Lau D, et al. Among authors: lara p. J Clin Oncol. 2001 Jan 15;19(2):442-7. doi: 10.1200/JCO.2001.19.2.442. J Clin Oncol. 2001. PMID: 11208837 Clinical Trial.

7

Prospective evaluation of cancer clinical trial accrual patterns: identifying potential barriers to enrollment.

Lara PN Jr, Higdon R, Lim N, Kwan K, Tanaka M, Lau DH, Wun T, Welborn J, Meyers FJ, Christensen S, O'Donnell R, Richman C, Scudder SA, Tuscano J, Gandara DR, Lam KS. Lara PN Jr, et al. J Clin Oncol. 2001 Mar 15;19(6):1728-33. doi: 10.1200/JCO.2001.19.6.1728. J Clin Oncol. 2001. PMID: 11251003

8

Gemcitabine in combination with new platinum compounds: an update.

Gandara DR, Edelman MJ, Lara PN, Lau DH. Gandara DR, et al. Among authors: lara pn. Oncology (Williston Park). 2001 Mar;15(3 Suppl 6):13-7. Oncology (Williston Park). 2001. PMID: 11301843 Free article. Review.

9

Neoadjuvant therapy for non-small cell lung cancer.

Gandara DR, Lara PN Jr, Goldberg Z, Roberts P, Lau DH. Gandara DR, et al. Among authors: lara pn jr. Anticancer Drugs. 2001 Feb;12 Suppl 1:S5-9. Anticancer Drugs. 2001. PMID: 11340902 Review.

10

Integration of new chemotherapeutic agents into chemoradiotherapy for stage III non--small cell lung cancer: focus on docetaxel.

Gandara DR, Lara PN Jr, Goldberg Z, Lau DH. Gandara DR, et al. Among authors: lara pn jr. Semin Oncol. 2001 Jun;28(3 Suppl 9):26-32. Semin Oncol. 2001. PMID: 11441412 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

608 results

Search Page

Filters